18F-Fluorocholine PET/CT in the Prediction of Molecular Subtypes and Prognosis for Gliomas

Clinical Nuclear Medicine - Tập 44 Số 10 - Trang e548-e558 - 2019
Ana María García Vicente1, Julián Pérez-Beteta2, Mariano Amo‐Salas3, Francisco José Pena Pardo1, Maikal Villena Martín4, Hernán Sandoval Valencia5, Manuela Mollejo Villanueva6, Rosa Barbella1, Christoph José Klein Zampaña5, José María Borrás Moreno4, Á.M. Soriano Castrejón1, Vı́ctor M. Pérez-Garcı́a2
1Nuclear Medicine Department, University General Hospital, Ciudad Real
2Mathematical Oncology Laboratory (MôLAB), Castilla La Mancha University, Ciudad Real
3Department of Mathematics, Castilla La Mancha University, Ciudad Real
4Neurosurgery Department. University General Hospital, Ciudad Real
5Neurosurgery Department, University General Hospital, Albacete
6Pathology Department, Complejo Hospitalario de Toledo, Toledo

Tóm tắt

Aim To study the association of metabolic features of 18F-fluorocholine in gliomas with histopathological and molecular parameters, progression-free survival (PFS) and overall survival (OS). Methods Prospective multicenter and nonrandomized study (Functional and Metabolic Glioma Analysis). Patients underwent a basal 18F-fluorocholine PET/CT and were included after histological confirmation of glioma. Histological and molecular profile was assessed: grade, Ki-67, isocitrate dehydrogenase status and 1p/19q codeletion. Patients underwent standard treatment after surgery or biopsy, depending on their clinical situation. Overall survival and PFS were obtained after follow-up. After tumor segmentation of PET images, SUV and volume-based variables, sphericity, surface, coefficient of variation, and multilesionality were obtained. Relations of metabolic variables with histological, molecular profile and prognosis were evaluated using Pearson χ2 and t test. Receiver operator caracteristic curves were used to obtain the cutoff of PET variables. Survival analysis was performed using Kaplan-Meier and Cox regression analysis. Results Forty-five patients were assessed; 38 were diagnosed as having high-grade gliomas. Significant differences of SUV-based variables with isocitrate dehydrogenase status, tumor grade, and Ki-67 were found. Tumor grade, Ki-67, SUVmax, and SUVmean were related to progression. Kaplan-Meier analysis revealed significant associations of SUVmax, SUVmean, and multilesionaly with OS and PFS. SUVmean, sphericity, and multilesionality were independent predictors of OS and PFS in Cox regression analysis. Conclusions Metabolic information obtained from 18F-fluorocholine PET of patients with glioma may be useful in the prediction of tumor biology and patient prognosis.

Từ khóa


Tài liệu tham khảo

2018, Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014, JAMA Oncol, 4, 1254, 10.1001/jamaoncol.2018.1789

2018, Glioma epigenetics: from subclassification to novel treatment options, Semin Cancer Biol, 51, 50, 10.1016/j.semcancer.2017.11.010

2015, Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors, N Engl J Med, 372, 2499, 10.1056/NEJMoa1407279

2018, Predicting IDH genotype in gliomas using FET PET radiomics, Sci Rep, 8, 13328, 10.1038/s41598-018-31806-7

2016, Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas, EurJ Nucl Med Mol Imaging, 43, 133, 10.1007/s00259-015-3140-4

2018, Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas, Eur J Nucl Med Mol Imaging, 45, 1573, 10.1007/s00259-018-4009-0

2015, Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses, Int J Cancer, 136, 2132, 10.1002/ijc.29259

2002, Pharmacokinetics and radiation dosimetry of 18F-fluorocholine, J Nucl Med, 43, 92

2017, Brain tumors: an update on clinical PET research in gliomas, Semin Nucl Med, 47, 5, 10.1053/j.semnuclmed.2016.09.004

2013, PET-based delineation of tumour volumes in lung cancer: comparison with pathological findings, Eur J Nucl Med Mol Imaging, 40, 1233, 10.1007/s00259-013-2407-x

2018, Tumor surface regularity at MR imaging predicts survival and response to surgery in patients with glioblastoma, Radiology, 288, 218, 10.1148/radiol.2018171051

2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1

2014, Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH, J Clin Oncol, 32, 783, 10.1200/JCO.2013.49.3726

2015, IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO, Acta Neuropathol (Berl), 129, 867, 10.1007/s00401-015-1438-8

2017, Diagnostic accuracy of neuroimaging to delineate diffuse gliomas within the brain: a meta-analysis, Am J Neurorad, 38, 1884, 10.3174/ajnr.A5368

2018, Spatial relationship of glioma volume derived from FET PET and volumetric MRSI: a hybrid PET-MRI study, J Nucl Med, 59, 603, 10.2967/jnumed.117.196709

1997, Brain tumors: detection with C-11 choline PET, Radiology, 202, 497, 10.1148/radiology.202.2.9015080

2007, Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET, Radiology, 244, 557, 10.1148/radiol.2442060898

1997, PET imaging of brain tumor with [methyl-11C]choline, J Nucl Med, 38, 842

2018, Is possible to establish the extent of resection of glioblastoma with 18F-fluorocholine PET/CT?, Clin Nucl Med, 43, e269, 10.1097/RLU.0000000000002153

2017, 18F-Fluorocholine PET/CT, brain-MRI and 5-aminolevulinic acid for the assessment of tumor resection in high-grade glioma, Clin Nucl Med, 42, e300, 10.1097/RLU.0000000000001643

2019, Ischemic complications after high-grade glioma resection could interfere with residual tumor detection with 18F-Fluorocholine PET/CT, Clin Nucl Med, 44, e76, 10.1097/RLU.0000000000002392

Segmentation of gliomas in 18F-Fluorocholine PET/CT. A multiapproach study, Rev Esp Med Nucl e Imag Molec

2017, 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria, Nucl Med Commun, 38, 242, 10.1097/MNM.0000000000000638

2012, Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head. A PET/MRI Evaluation, Clin Nucl Med, 37, e196, 10.1097/RLU.0b013e31824c5dd0

2001, Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging, Eur J Nucl Med, 28, 1664, 10.1007/s002590100620

2002, 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography, Mol Imaging Biol, 4, 267, 10.1016/S1536-1632(02)00015-X

2017, Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?, EJNMMI Res, 7, 48, 10.1186/s13550-017-0295-y

2015, Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer, World J Gastroenterol, 21, 5901, 10.3748/wjg.v21.i19.5901

2004, Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors, Eur J Nucl Med Mol Imaging, 31, 1064

2007, FET PET for the evaluation of untreated gliomas: correlationof FET uptake and uptake kinetics with tumour grading, Eur J Nucl Med Mol Imaging, 34, 1933, 10.1007/s00259-007-0534-y

2011, Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PETfor glioma grading: assessment of individual probability of malignancy, Clin Nucl Med, 36, 841, 10.1097/RLU.0b013e3182291b40

2015, Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas, Eur Radiol, 25, 3017, 10.1007/s00330-015-3691-6

2016, The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers, Eur J Nucl Med Mol Imaging, 43, 2360, 10.1007/s00259-016-3452-z

2018, Diagnostic accuracy of MRI texture analysis for grading gliomas, J Neurooncol, 140, 583, 10.1007/s11060-018-2984-4

2018, Quantitative texture analysis in the prediction of IDH status in low-grade gliomas, Clin Neurol Neurosurg, 164, 114, 10.1016/j.clineuro.2017.12.007

2007, Apparent diffusion coefficienthistograms may predict low-grade glioma subtype, NMR Biomed, 20, 49, 10.1002/nbm.1091

2014, Improving tumour heterogeneity MRI assessment with histograms, Br J Cancer, 111, 2205, 10.1038/bjc.2014.512

2013, Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas, Oncol Letters, 6, 130, 10.3892/ol.2013.1317

2017, Is the information provided by aminoacid PET radiopharmaceuticals clinically equivalent in gliomas?, Eur J Nucl Med Mol Imaging, 44, 1408, 10.1007/s00259-017-3710-8

2018, Static and dynamic 18F-FET PET for characterization of gliomas defined by IDH and 1p/19q status, Eur J Nucl Med Mol Imaging, 45, 443, 10.1007/s00259-017-3846-6

2012, Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas, Neuro Oncol, 14, 1473, 10.1093/neuonc/nos259

2016, Prognostic value of O-(2-[18F]- fluoroethyl)-L-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma, World Neurosurg, 89, 230, 10.1016/j.wneu.2016.01.085

2017, IDH mutation is paradoxicallyassociated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas, Eur J Nucl Med Mol Imaging, 44, 1306, 10.1007/s00259-017-3668-6

2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229

2012, 1P19Q loss but not IDH1 mutations influencesWHO grade II gliomas spontaneous growth, J Neurooncol, 108, 69, 10.1007/s11060-012-0831-6

2018, Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status, Eur J Nucl Med Mol Imaging, 45, 1242, 10.1007/s00259-018-3969-4

2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 32, 1807

2014, Integrated DNA methylation and copy-number profiling identifythree clinically and biologically relevant groups of anaplasticglioma, Acta Neuropathol, 128, 561, 10.1007/s00401-014-1315-x

2010, Patients with IDH1-wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutatedglioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classificationof gliomas, Acta Neuropathol, 120, 707, 10.1007/s00401-010-0781-z

2015, Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis, Asian Pac J Cancer Prev, 16, 411, 10.7314/APJCP.2015.16.2.411

2017, Radiomic analysis reveals prognostic information in T1-weighted baseline magnetic resonance imaging in patients with glioblastoma, Invest Radiol, 52, 360, 10.1097/RLI.0000000000000349

2016, Prognostic imaging biomarkers in glioblastoma: development and independent validation on the basis of multiregion and quantitative analysis of MR images, Radiology, 278, 546, 10.1148/radiol.2015150358

2018, Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma, Neuro Oncol, 20, 279, 10.1093/neuonc/nox153

2018, Prognostic value of the metabolic and volumetric parameters of 11C-methionine positron-emission tomography for gliomas: a systematic review and meta-analysis, Am J Neuroradiol, 39, 1629, 10.3174/ajnr.A5707

Thông tin
Thông tin xuất bản

Clinical Nuclear Medicine

Tập 44 Số 10

e548-e558

Thông tin tác giả